CureVac inks strategic mRNA technology deal with GSK

20 July 2020

Clinical-stage German biotech CureVac has signed a strategic collaboration with UK pharma major GlaxoSmithKline (LSE: GSK) on mRNA vaccine and monoclonal antibody (MAb) research.

The agreement covers the research, development, manufacturing and commercialization of up to five mRNA-based vaccines and MAbs targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA capabilities with CureVac’s integrated mRNA platform.

CureVac came to international attention in the early stages of the novel coronavirus pandemic, when it was reported that US President Donald Trump “had offered funds” to entice the company to move its recently started COVID-19 R&D work to the USA. This perceived threat led to the German government investing 300 million euros ($338 million) in the biotech company, taking a 23% stake in the firm. However, CureVac’s existing COVID-19 mRNA and rabies vaccines research programs are not included in the collaboration with GSK announced today.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK